Anyone interested in Medlive Technology Co., Ltd. (HKG:2192) should probably be aware that the VP, Deputy Head of Medical Information Science Research Unit & Executive Director, Lijun Tian, recently divested HK$3.6m worth of shares in the company, at an average price of HK$15.02 each. That sale was 27% of their holding, so it does make us raise an eyebrow.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Medlive Technology Insider Transactions Over The Last Year

Notably, that recent sale by Lijun Tian is the biggest insider sale of Medlive Technology shares that we've seen in the last year. So what is clear is that an insider saw fit to sell at around the current price of HK$15.02. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.

Lijun Tian divested 451.00k shares over the last 12 months at an average price of CN¥15.05. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

View our latest analysis for Medlive Technology

For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.

Does Medlive Technology Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that Medlive Technology insiders own 1.6% of the company, worth about HK$174m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At Medlive Technology Tell Us?

An insider sold Medlive Technology shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. On the plus side, Medlive Technology makes money, and is growing profits. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. At Simply Wall St, we've found that Medlive Technology has 2 warning signs (1 is potentially serious!) that deserve your attention before going any further with your analysis.

But note: Medlive Technology may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.